Page 1

Olema CONCOLOGY Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update May 11 , 2021 • OP - 1250 continues to advance in dose - escalation stage of Phase 1/2 clinical trial in patients with metastatic , ER + / HER2- breast cancer ; Initial data anticipated in 2H 2021 • Cash , cash equivalents , and marketable securities of $ 327.0 million as of March 31 , 2021 sufficient to fund operations through the end of 2023 SAN FRANCISCO , May 11 , 2021 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals , Inc. ( " Olema " or " Olema Oncology , " Nasdaq : OLMA ) , a clinical - stage biopharmaceutical company focused on the discovery , development and commercialization of targeted therapies for women's cancers , today provided an update on recent company developments and reported first quarter financial results for the period ended March 31 , 2021 . " The first quarter of 2021 was very productive for Olema as we continued to advance our wholly - owned lead candidate , OP - 1250 , a complete estrogen receptor ( ER ) antagonist ( CERAN ) , through dose escalation in the ongoing Phase 1/2 clinical trial in ER + / HER2- breast cancer , and made substantial progress in building our organization , " said Sean P. Bohen , M.D. , Ph.D. , President and Chief Executive Officer of Olema Oncology . " Looking ahead , we remain on track to share initial clinical data at a medical meeting later this year and advance OP - 1250 into Phase 2 monotherapy expansion . We also plan to initiate a Phase 1b study to evaluate OP - 1250 in combination with a CDK4 / 6 inhibitor in the second half of 2021. We are in a strong financial position to execute on our strategy and are committed to working toward advancing the standard of care for people living with breast cancer . " Recent Corporate Highlights • Presented nonclinical data on OP - 1250 in a late - breaking poster session at the American Association for Cancer Research ( AACR ) Annual Meeting , held virtually from April 10-15 , 2021. Data presented showed that 10 mg / kg OP - 1250 , a complete estrogen receptor ( ER ) antagonist ( CERAN ) , was superior to tamoxifen , fulvestrant and ovariectomy in shrinking mutant ESR1 - Y537S tumors in an intracranial model of ER + breast cancer brain metastasis . • Appointed Yi Larson to Olema's Board of Directors in April 2021. Ms. Larson currently serves as Chief Financial Officer at LianBio and brings significant biotech operational leadership and global healthcare banking expertise . • Strengthened Olema's research and discovery capabilities with the opening of new laboratory facilities in San Francisco , CA. Financial Highlights • Cash , cash equivalents and marketable securities as of March 31 , 2021 were $ 327.0 million . Olema anticipates that this balance of cash will be sufficient to fund operations through the end of 2023 . • Net loss for the quarter ended March 31 , 2021 was $ 15.3 million , compared to $ 1.7 million for the same period of the prior year . • Research and development ( R & D ) expenses were $ 10.7 million for the quarter ended March 31 , 2021 , compared to $ 0.8 million for the same period of the prior year . The increase in R & D expenses was primarily related to the increase in nonclinical development activities , execution of the ongoing Phase 1/2 clinical trial of OP - 1250 and higher non - cash stock - based compensation expenses . • General and administrative ( G & A ) expenses were $ 4.8 million for the quarter ended March 31 , 2021 , compared to $ 0.2 million for the same period of the prior year . The increase in G & A expenses was primarily related to an increase in personnel , public company - related expenses , other corporate costs and higher non - cash stock - based compensation expenses . About Olema Oncology Olema Oncology is a clinical - stage biopharmaceutical company focused on the discovery , development and commercialization of targeted therapies